Literature DB >> 1728533

Functional analysis of peripheral blood lymphocytes isolated from patients with chronic hepatitis type B.

C García-Monzón1, R Moreno-Otero, L García-Buey, M López-Botet, M O De Landázuri, F Sánchez-Madrid.   

Abstract

Cell-mediated immunity, evaluated by lymphocyte proliferation and expression of the activation antigen interleukin-2 receptor in response to mitogens such as phytohemagglutinin and concanavalin-A, has been reported to be defective in chronic hepatitis B virus carriers. However, no definite conclusion on the functional state of T cells from these patients can be drawn. In the present study, we have investigated the expression of a wide set of lymphoid activation molecules as well as the proliferative response of peripheral blood lymphocytes isolated from patients with chronic hepatitis type B after in vitro stimulation with monoclonal antibodies to both the T-cell receptor-CD3 complex and the CD2 molecule, which are the two main T-cell activation pathways. Our findings show that peripheral T lymphocytes from patients with chronic hepatitis type B express the activation antigens 4F2 molecule, interleukin-2 receptor, and activation inducer molecule (AIM) antigen, and proliferate normally after specific stimulation through either the T-cell receptor-CD3 complex or the CD2 molecule. These results suggest that the peripheral blood T cells of patients with chronic hepatitis B are fully operative and functionally competent in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1728533     DOI: 10.1007/bf01308345

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Inhibition of Na+/Ca2+ exchanger activity in cardiac and skeletal muscle sarcolemmal vesicles by monoclonal antibody 44D7.

Authors:  M Michalak; E J Quackenbush; M Letarte
Journal:  J Biol Chem       Date:  1986-01-05       Impact factor: 5.157

2.  Involvement of the CD4 molecule in a post-activation event on T cell proliferation.

Authors:  A C Carrera; F Sanchez-Madrid; M Lopez-Botet; C Bernabeu; M O De Landazuri
Journal:  Eur J Immunol       Date:  1987-02       Impact factor: 5.532

3.  Thymus-dependent lymphocyte function in patients with hepatitis-associated antigen.

Authors:  V Giustino; F J Dudley; S Sherlock
Journal:  Lancet       Date:  1972-10-21       Impact factor: 79.321

4.  Hepatitis B virus DNA in liver and peripheral blood mononuclear cells during reduction in virus replication.

Authors:  J Bartolomé; G Moraleda; J Molina; F Dominguez; J C Porres; V Carreño
Journal:  Gastroenterology       Date:  1990-12       Impact factor: 22.682

5.  An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein.

Authors:  S C Meuer; R E Hussey; M Fabbi; D Fox; O Acuto; K A Fitzgerald; J C Hodgdon; J P Protentis; S F Schlossman; E L Reinherz
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

6.  Acute and chronic hepatitis revisited. Review by an international group.

Authors: 
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

7.  Detection of hepatitis B virus DNA in mononuclear blood cells.

Authors:  P Pontisso; M C Poon; P Tiollais; C Brechot
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-26

8.  Leucocyte hepatitis B virus DNA in acute and chronic hepatitis B virus infection.

Authors:  F Davison; G J Alexander; C Anastassakos; E A Fagan; R Williams
Journal:  J Med Virol       Date:  1987-08       Impact factor: 2.327

9.  Hepatitis B virus DNA in mononuclear blood cells. A frequent event in hepatitis B surface antigen-positive and -negative patients with acute and chronic liver disease.

Authors:  C Pasquinelli; F Lauré; L Chatenoud; G Beaurin; C Gazengel; H Bismuth; F Degos; P Tiollais; J F Bach; C Bréchot
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

10.  Interleukin-2 activity in chronic active liver diseases: response by T cells and in the autologous mixed lymphocyte reaction.

Authors:  K Yoshioka; S Kakumu; H Murakami; K Fukui
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.